Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AR-mTOR-26 |
Synonyms | |
Therapy Description |
AR-mTOR-26 is a selective inhibitor of mTOR, which leads to decreased signaling through mTORC1 and mTORC2, and may lead to decreased tumor growth (Cancer Res April 15, 2010 70; 4484, PMID: 20024839). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AR-mTOR-26 | AR mTOR 26 | mTOR Inhibitor 51 | AR-mTOR-26 is a selective inhibitor of mTOR, which leads to decreased signaling through mTORC1 and mTORC2, and may lead to decreased tumor growth (Cancer Res April 15, 2010 70; 4484, PMID: 20024839). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | prostate cancer | predicted - sensitive | AR-mTOR-26 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, AR-mTOR-26 treatment resulted in antitumor activity in prostate cancer xenograft models with PTEN loss (Cancer Res 2010;70(8 Suppl):Abstract nr 4484). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|